Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Adenosine A(2A) receptors (A2AR) blockade shows neuroprotective effects in brain injury.
• Mechanisms of A2AR-mediated neuroprotection, particularly regarding neuroinflammation, are not fully understood.
• A2AR are known to modulate peripheral inflammation.

Purpose of the Study:

• To investigate if A2AR antagonism attenuates lipopolysaccharide (LPS)-induced neuroinflammation and neuronal dysfunction in the hippocampus.
• To determine the role of A2AR in LPS-induced microglial activation and inflammatory mediator release.

Main Methods:

• Intracerebroventricular injection of a selective A2AR antagonist (SCH58261) in rats.
• Intraperitoneal administration of lipopolysaccharide (LPS) to induce neuroinflammation.
• Assessment of long-term potentiation (LTP) as a measure of synaptic plasticity.
• Measurement of inflammatory mediators (interleukin-1β) and cellular markers (activated microglia, p38, c-jun N-terminal kinase, caspase 3).

Main Results:

• LPS administration significantly reduced LTP and increased inflammatory markers and cellular stress pathways in the hippocampus.
• SCH58261 treatment attenuated LPS-induced decreases in LTP.
• SCH58261 prevented LPS-induced increases in p38 and c-jun N-terminal kinase phosphorylation, caspase 3 activation, microglial activation, and interleukin-1β levels.

Conclusions:

• A2AR activation is critical for mediating LPS-induced neuroinflammation and neuronal dysfunction.
• A2AR antagonists, like SCH58261, can prevent neuroinflammation by inhibiting microglial activation and inflammatory responses.
• These findings support the therapeutic potential of A2AR antagonists in neurodegenerative diseases associated with neuroinflammation.